Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) have received an average recommendation of "Hold" from the five brokerages that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $3.67.

LXRX has been the topic of several research reports. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. Leerink Partners reissued a "market perform" rating and set a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday. Piper Sandler decreased their price target on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd.

Lexicon Pharmaceuticals Price Performance

LXRX traded up $0.02 on Friday, reaching $0.39. The company had a trading volume of 13,534,445 shares, compared to its average volume of 4,048,527. The company has a market cap of $96.48 million, a price-to-earnings ratio of -0.52 and a beta of 1.04. Lexicon Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $2.83. The business has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $1.14. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Remove Ads

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. As a group, sell-side analysts anticipate that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LXRX. FMR LLC increased its stake in shares of Lexicon Pharmaceuticals by 28.9% in the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company's stock worth $78,291,000 after buying an additional 11,179,919 shares during the period. Point72 Asset Management L.P. boosted its holdings in Lexicon Pharmaceuticals by 630.7% in the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock valued at $6,638,000 after acquiring an additional 7,758,371 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its holdings in Lexicon Pharmaceuticals by 301.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock valued at $5,582,000 after acquiring an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in Lexicon Pharmaceuticals by 186.6% in the fourth quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company's stock valued at $4,877,000 after acquiring an additional 4,300,000 shares in the last quarter. Finally, Tang Capital Management LLC boosted its holdings in Lexicon Pharmaceuticals by 750.3% in the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock valued at $628,000 after acquiring an additional 750,268 shares in the last quarter. 74.70% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.